Home

IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents

Daniel Carlson -
0
TW's Take: positive execution on their business strategy which positions them even better for potential partnering activity. ~ Newly granted patents expand the use of...
Read more

Anixa Biosciences Establishes Cancer Business Advisory Board

Daniel Carlson -
0
TW's Take: this is a very strong group of individuals. Hopefully the establishment of this board leads to a meaningful partnership on one or...
Read more

Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate...

Daniel Carlson -
0
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine...
Read more

Meaningful Catalysts

Daniel Carlson -
8
This week the heat finally turned off here in Charlottesville with temperatures coming down from the 90's to a more reasonable level. Despite school...
Read more

Spectra7 Announces Convertible Debenture Unit Financing

Daniel Carlson -
0
TW's Take: needed capital as we await a contract from a North American data center operator. Fingers crossed it's soon, but delays are weighing...
Read more

Is the Ice Thawing? XBI Acting Slightly Better…

Daniel Carlson -
0
This past week was dreadfully dull. Volume across the board was anemic and the tone from traders was muted. August may in fact be...
Read more

INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and...

Daniel Carlson -
0
TW's Take: good news as this approval should not only accelerate enrollment but is a positive sign as we await expected EU and FDA...
Read more

Wrapping up Summer

Daniel Carlson -
1
Sadly, the dog days of summer are over. September is here and investment bankers, traders and most of Europe will be returning to work....
Read more

Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial

Daniel Carlson -
0
TW's Take: enrollment is finally picking up and the therapy has shown an excellent safety profile and some moderate efficacy at the initial, sub-therapeutic...
Read more

Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of...

Daniel Carlson -
0
TW's Take: RADR is a powerful tool. How Lantern will monetize this remains the biggest question mark around the product. Eventually the value of...
Read more

Know What You Own…

Daniel Carlson -
2
"The single most important thing for me in the stock market is to know what you own." ~ Peter Lynch It's tough out there. Markets are...
Read more

Spectra7 Announces Second Quarter 2023 Financial Results

Daniel Carlson -
0
TW's Take: the story inches closer to success. Spectra7 is well positioned for the upgrade cycle that looks likely to commence around YE 2023. Record...
Read more

Fitch Kills The Rally

Daniel Carlson -
1
Inflation data keeps coming down, analysts continue to see an end to rate increases, yet markets are weak. What gives? My opinion, it all...
Read more

TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Daniel Carlson -
2
TW's Take: much needed capital provides a runway through data in Q4. Insider participation in the financing is a positive and it's now time...
Read more

Premium Subscriber Update: TFF Raises Money at $0.25…What Does It Mean?

Daniel Carlson -
6
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual...

Daniel Carlson -
0
TW's Take: more scientific validation for this unique therapy provides further evidence of a potentially blockbuster solid-tumor cancer platform. SAN JOSE, Calif., Aug. 14, 2023 /PRNewswire/ -- Anixa...
Read more

INmune Updates Shareholders and Other Thoughts

Daniel Carlson -
6
The big news this past week was INmune (INMB)'s earnings release and conference call. Or was it? The stock was down over 10% on...
Read more

IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility

Daniel Carlson -
0
TW's Take: State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline of innovative gamma-delta T cell therapies The...
Read more

Evie Ring Establishes Medical Advisory Board Furthering its Commitment to Bringing a Medical-Grade Wearable...

Daniel Carlson -
0
The women-led board will leverage their medical and scientific expertise to enhance Evie's product roadmap and provide trusted content PLEASANTON, Calif., Aug. 10, 2023 /PRNewswire/ -- Today, Movano...
Read more

Could Anixa Biosciences (NASDAQ:ANIX) Be Developing The Vaccine To End One Of The Deadliest...

Daniel Carlson -
0
TW's Take: my thinking behind this "news story" is that management is frustrated by the lack of value being assigned to the company in...
Read more

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

Premium Membership

For those interested in doing a deeper dive into our coverage universe, we offer premium membership. Benefits of being a premium member include the following:

First Look: new names added to the portfolio, or stocks being removed, are shared with premium subscribers before anyone else.

Trade Alerts: when actionable events occur, we highlight the opportunities in an email to our premium subscribers

TW Private Chat Room: premium members have access to our exclusive chat room where more research and ideas are freely shared amongst the whole community.

SIGN ME UP

© TW Research Group LLC
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.